A Study of PY314 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-10-28
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects
with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or
relapsed to standard of care (including pembrolizumab, if approved for that indication).